1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Endometrial cancers

Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Technology appraisal guidance [TA779] Published: 16 March 2022

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 144 KB 08 February 2022  
  • Managed access agreement PDF 370 KB 08 February 2022  
  • Equality Impact Assessment (Guidance development) PDF 145 KB 16 March 2022  

Final draft guidance: 1

  • Final draft guidance: 1  
  • Public committee slides PDF 1.34 MB 08 February 2022  
  • Committee papers PDF 6.08 MB 08 February 2022  
  • Final appraisal document PDF 261 KB 08 February 2022  

Invitation to participate

  • Draft scope and provisional stakeholder list comments table (post-referral) PDF 319 KB 16 March 2021  
  • Final scope PDF 186 KB 16 March 2021  
  • Final stakeholder list PDF 161 KB 16 March 2021  
  • Equality impact assessment (Scoping) PDF 124 KB 16 March 2021  

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators  
  • Draft scope post referral PDF 177 KB 12 October 2020  
  • Draft matrix post referral PDF 160 KB 03 November 2020